BC43 Inter-amer 30

     
BW20020814002334  20020814T155615Z UTC


( BW)(ELI-LILLY-&-CO)(BC43) Miscellaneous

    Business Editors
    UK REGULATORY NEWS

  INDIANAPOLIS--(BW HealthWire)--Aug. 14, 2002--

             Crenshaw Takes New VP Role at Lilly; Bingham
      Appointed e.Lilly VP; West Promoted to Executive Director

Newt Crenshaw, currently vice president of e.Lilly, has been
appointed to the newly created role of vice president of
communications and public affairs at Eli Lilly and Company. Crenshaw
will have responsibility for internal, external, and executive
communications; corporate crisis and issues management; philanthropy,
community affairs, and global guest relations; and the Lilly brand. He
will remain a member of the senior management forum.

Crenshaw will report to Deborah Steelman, vice president of global
corporate affairs. Steelman will continue to lead Lilly corporate
affairs, but Crenshaw's new role will allow her to place greater focus
on activities that support the company's demand realization efforts.
Steelman will join the sales and marketing executive committee, led by
Gerhard Mayr, executive vice president of pharmaceutical operations.

"The new structure for corporate affairs will provide Deborah with
the opportunity to create closer partnerships with the pharmaceutical
products and global marketing and sales organizations," said Lilly
Chairman, President and CEO Sidney Taurel. "Newt will provide
executive leadership to ensure integration of communications, focus on
the Lilly brand, and management of issues and crises."

Alph Bingham, Ph.D., vice president of e.Lilly research and
development, has accepted the position of vice president of e.Lilly,
succeeding Crenshaw. He will report to John Lechleiter, Ph.D.,
executive vice president of pharmaceutical products and corporate
development, and will join the senior management forum

In recognition of his expertise in and the increasing complexity
and importance of external communications, Ed West, currently director
of public relations, has been promoted to executive director of public
relations. He will report to Crenshaw and will continue to have
responsibility for global media relations and marketing
communications.

Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of best-in-class pharmaceutical products by applying
the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers - through medicines and
information - for some of the world's most urgent medical needs.
Additional information about Lilly is available at www.lilly.com.

   Short Name: LLY
   Category Code: MSC
   Sequence Number: 00000635
   Time of Receipt (offset from UTC): 20020814T154539+0100

    --30--djl/cl*

    CONTACT:  Eli Lilly and Company
              Joan Todd, 317/433-0121

    KEYWORD:  INDIANA
    INDUSTRY KEYWORD:  MEDICAL PHARMACEUTICAL EARNINGS
    SOURCE: Lilly (Eli) & Co

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com

Inter-amer 30 (LSE:BC43)
Historical Stock Chart
From Mar 2025 to Apr 2025

Inter-amer 30 (LSE:BC43)
Historical Stock Chart
From Apr 2024 to Apr 2025